Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

ClinicalTrials.gov ID: NCT02814643

Public ClinicalTrials.gov record NCT02814643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.

Study identification

NCT ID
NCT02814643
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
103 participants

Conditions and interventions

Conditions

Interventions

  • Benralizumab Drug
  • Benralizumab Placebo Drug
  • Seasonal influenza virus vaccine Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2016
Primary completion
Jan 23, 2017
Completion
Jan 23, 2017
Last update posted
Oct 23, 2018

2016 – 2017

United States locations

U.S. sites
24
U.S. states
13
U.S. cities
22
Facility City State ZIP Site status
Research Site Birmingham Alabama 35209
Research Site Mesa Arizona 85206
Research Site Huntington Beach California 92647
Research Site Newport Beach California 92663
Research Site Aurora Colorado 80012-4016
Research Site Colorado Springs Colorado 80907
Research Site Denver Colorado 80230
Research Site Aventura Florida 33180
Research Site Miami Florida 33135
Research Site Miami Florida 33173
Research Site Minneapolis Minnesota 55402
Research Site Bellevue Nebraska 68123
Research Site Northfield New Jersey 08225
Research Site Edmond Oklahoma 73034
Research Site Oklahoma City Oklahoma 73103
Research Site Medford Oregon 97504
Research Site North Charleston South Carolina 29420
Research Site Arlington Texas 76018
Research Site El Paso Texas 79903
Research Site New Braunfels Texas 78130
Research Site San Antonio Texas 78221
Research Site San Antonio Texas 78251
Research Site Waco Texas 76712
Research Site Clinton Utah 84015

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02814643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 23, 2018 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02814643 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →